Role of dietary salt in hypertension

Life Sciences

Volumn 79, Issue 17, 2006, Pages 1585-1592

  Haddy, Francis J ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Diet; Hypertension; Ouabain; Salt

Indexed keywords

17BETA (3 FURYL) 5BETA ANDROSTANE 3BETA,14BETA,17ALPHA TRIOL; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM) INHIBITOR; BUFADIENOLIDE; CANRENONE; CARDENOLIDE; DIGITALIS LIKE FACTOR; DIGITOXIGENIN; DIGOXIN ANTIBODY F(AB) FRAGMENT; DIURETIC AGENT; MARINOBUFAGENIN; OUABAIN; SODIUM CHLORIDE; STEROID; UNCLASSIFIED DRUG;

ADRENAL GLAND; BLOOD VOLUME; DRUG INDICATION; HUMAN; HYPERTENSION; NONHUMAN; POTASSIUM INTAKE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE; SODIUM CELL LEVEL; SODIUM RESTRICTION; STEROID RELEASE; URINARY EXCRETION;

ANIMALS; BLOOD PRESSURE; DIET, SODIUM-RESTRICTED; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; HYPERTENSION; NA(+)-K(+)-EXCHANGING ATPASE; OUABAIN; SODIUM CHLORIDE, DIETARY;

STROPHANTHUS GRATUS;

EID: 33748425247     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2006.05.017     Document Type: Review

References (105)

1. Adair C.D., Buckalew V., Taylor K., Ernest J.M., Frye A.H., Evans C., and Veille J.-C. Elevated endoxin-like factor complicating a multifetal second trimester pregnancy: treatment with digoxin-binding immunoglobulin. American Journal of Nephrology 16 (1996) 529-531
2. Ambrosioni E., Costa F.V., Montebugnoli L., Fartagni F., and Magnani B. Increased intralymphocytic sodium content in essential hypertension. Clinical Science 61 (1981) 181-186
3. Bagrov A.Y., and Fedorova O.V. Cardenolide and bufadienolide ligands of the sodium pump. How they work together in NaCl sensitive hypertension. Frontiers in Bioscience 10 (2005) 2250-2256 (Sept 1)
4. Bagrov A.Y., Fedorova O.V., Dmitrieva R.I., French A.W., and Anderson D.E. Endogenous marinobufagenin-like immunoreactive substance. A possible endogenous NaKATPase inhibitor with vasoconstrictor activity. American Journal of Hypertension 9 (1996) 982-990
5. Bagrov A.Y., Fedorova O.V., Dmitrieva R.I., French A.W., and Anderson D.E. Plasma marinobufogenin-like and ouabain-like immunoreactivity during saline volume expansion in anesthetized dogs. Cardiovascular Research 31 (1996) 296-305
6. +-ATPase inhibitor in patients with myocardial infarction. Hypertension 31 (1998) 1097-1103
7. Bagrov A.Y., Manusova M.B., Egorova I.A., and Fedorova O.V. Endogenous digitalis-like ligands and Na/K-APTase inhibition in experimental diabetes mellitus. Frontiers in Bioscience 10 (2005) 2257-2262 (Sept 1)
8. Blaustein M. Sodium ions, calcium ions, blood pressure regulation and hypertension: a reassessment and a hypothesis. American Journal of Physiology 232 (1977) C165-C173
9. Blaustein M.P. Physiological effects of endogenous ouabain: control of intracellular calcium stores and cell responsiveness. American Journal of Physiology 264 (1993) C1367-C1387
10. Buckalew V.M. Endogenous digitalis-like factors. An historical overview. Frontiers in Bioscience 10 (2005) 2325-2334
11. +) pump activity in low renin hypertension. Clinical Research 30 (1982) 733A
12. Canessa M., Adragna N., Solomon H.S., Connolly B.S., and Tosteson D.C. Increased sodium-lithium countertransport in red cells of patients with essential hypertension. New England Journal of Medicine 302 (1980) 772-776
13. Chen W.T., Brace R.A., Scott J.B., Anderson D.K., and Haddy F.J. The mechanism of the vasodilator action of potassium. Proceedings of the Society for Experimental Biology and Medicine 140 (1972) 820-824
14. Chen S., Yuan C., Clough D., Schooley S., Haddy F.J., and Pamnani M.B. Role of digitalis like substance in the hypertension of streptozotocin induced diabetes in reduced renal mass rats. American Journal of Hypertension 6 (1993) 397-406
15. Chen S., Yuan C., Clough D., Haddy F.J., and Pamnani M.B. Role of digitalis-like substance in experimental insulin dependent diabetes mellitus hypertension. Journal of Cardiovascular Pharmacology 22 suppl 2 (1993) s20-s21
16. +-ATPase in rats with one-kidney Goldblatt hypertension. Federation Proceedings 36 (1977) 491
17. +-ATPase in rats with one-kidney Goldblatt hypertension. The Physiologist 20 (1977) 18
18. Conway J. Hemodynamic consequences of induced changes in blood volume. Circulation Research 18 (1966) 190-198
19. Cress L.W., Freas W., Haddy F., and Muldoon S. Effects of bufalin on norepinephrine turnover in canine saphenous vein. Hypertension 18 (1991) 516-522
20. deWardener H.E., and Clarkson E.N. A concept of natriuretic hormone. Physiological Reviews 65 (1985) 658-759
21. +-adenosine triphosphatase in vitro. Lancet 1 (1981) 411-412
22. Edmonson R.P.S., Thomas R.D., Hilton P.J., Patrick J., and Jones N.F. Abnormal leukocyte composition and sodium transport in essential hypertension. Lancet 1 (1975) 1003-1005
23. Eliades D., Swindall B., Johnston J., Pamnani M., and Haddy F. Hemodynamic effects of bufalin in the anesthetized dog. Hypertension 13 (1989) 690-695
24. Eliades D., Pamnani M.B., Swindall B.T., and Haddy F.J. Effects of bufalin on renal venous outflow, urine flow and natriuresis in the anesthetized dog. In: Cox R.H. (Ed). Cellular and Molecular Mechanisms of Hypertension (1991), Plenum Press, New York 205-210
25. Epstein M. Cardiovascular and renal effects of head-out water immersion in man. Application of the model in assessment of volume homeostasis. Circulation Research 39 (1976) 619-628
26. Epstein M. Renal effects of head-out immersion in man. Physiological Reviews 58 (1978) 529-581
27. Epstein M., Bricker N.S., and Bourgoignie J.J. Presence of a natriuretic factor in urine of normal man undergoing water immersion. Kidney International 13 (1978) 152-158
28. Fedorova O.V., Doris P.A., and Bagrov A.Y. Endogenous marinobufagenin-like factor in acute volume expansion. Clinical and Experimental Hypertension 20 (1998) 581-593
29. Fedorova O.V., Talan M.I., Ogalokova N.I., Lakota E.G., and Bagrov A.Y. Endogenous ligand of alpha, sodium pump, marinobufagenin, is a novel mediator of sodium chloride-dependent hypertension. Circulation 105 (2002) 1122-1127
30. Fedorova O.V., Kolodkin N.I., Agalakova N.I., Namicas A.R., Bzhelyansky A., St-Louis J., Lakatta E.G., and Bagrov A.Y. Antibody to marinobufagenin lowers blood pressure in pregnant rats on a high NaCl intake. Journal of Hypertension 23 (2005) 835-842
31. Ferrandi M., Manunta P., Ferrari P., and Bianchi G. Endogenous ouabain: molecular basis of its role in hypertension and cardiovascular complications. Frontiers in Bioscience 10 (2005) 2472-2477 (Sept 1)
32. Friedman S.M. An ion exchange approach to the problem of intracellular sodium in the hypertensive process. Circulation Research 34 & 35 (1975) 1-123-1-128
33. Friedman S.M. Evidence for enhanced sodium transport in the tail artery of the spontaneously hypertensive rat. Hypertension 1 (1979) 572-582
34. Friedman S.M., and Friedman C.L. Cell permeability, sodium transport, and the hypertensive process in the rat. Circulation Research 39 (1976) 433-441
35. + in the spontaneously hypertensive rat. Experientia 32 (1976) 476-478
36. + co-transport system in erythrocytes from essential hypertension. Nature 284 (1980) 281
37. Goto A., Ishiguro T., Yamoda K., Ishii M., Yoshioka M., Eguchi C., Shimura M., and Sugimoto T. Isolation of an urinary digitalis-like factor indistinguishable from digoxin. Biochemical and Biophysical Research Communications 173 (1990) 1093-1101
38. Gottlieb S.S., Rogowski A.C., Weinberg M., Krichten C.M., Hamilton B.C., and Hamlyn J.M. Elevated concentrations of endogenous ouabain in patients with congestive heart failure. Circulation 86 (1992) 420-425
39. Gruber K.A., Whitaker J.M., and Buckalew V.M. Endogenous digitalis-like substance in plasma of volume expanded dogs. Nature 287 (1980) 743-745
40. Haddy F.J. Role of a ouabain-like humoral agent and the sodium-potassium pump in low-renin hypertension. In: Villarreal H., and Sambhi M.P. (Eds). Topics in Pathophysiology of Hypertension (1984), Martinus Nyhoff Publishers, Boston 223-238
41. Haddy F.J. Digitalis-like circulating factor in hypertension: potential messenger between salt balance and intracellular sodium. Cardiovascular Drugs and Therapy 4 (1990) 343-349
42. Haddy F.J., and Overbeck H.W. The role of humoral agents in volume expanded hypertension. Life Sciences 19 (1976) 935-948
43. Haddy F.J., and Pamnani M.B. Pharmacologic agents for the in vivo detection of vascular sodium transport defects in hypertension. Life Science 41 (1987) 2685-2696
44. Haddy F.J., and Pamnani M.B. Role of dietary salt in hypertension. Journal of the American College of Nutrition 14 (1995) 428-438
45. Haddy F.J., Pamnani M., and Clough D. The sodium-potassium pump in volume expanded hypertension. Clinical and Experimental Hypertension 1 (1978) 295-336
46. Haddy F.J., Pamnani M.B., and Clough D.L. Pathophysiological role of cation transport and natriuretic factors in hypertension. Hypertension 10 suppl 1 (1987) 1-101-1-107
47. +)-ATPase associated with essential hypertension. Nature 300 (1982) 1-3
48. Hamlyn J.M., Blaustein M.P., Bova S., duCharme V.W., Harris D.W., Mandel F., Matthews W.R., and Ludens J.H. Identification and characterization of a ouabain-like compound from human plasma. Proceedings of the National Academy of Sciences of the United States of America 88 (1991) 6259-6263
49. Hamlyn J.M., Manunta P., and Hamilton B.P. Endogenous ouabain in the pathogenesis of hypertension and cardiovascular disorders. In: Laragh J.H., and Brenner B.M. (Eds). Hypertension, Pathophysiology, Diagnosis and Management. 2nd ed (1995), Raven Press, New York 1077-1081
50. Hamlyn J.M., Lu Z., Manunta P., LLudens J.H., Kimura K., Shah J.R., Larado J., Hamilton J.P., Hamilton M.J., and Hamilton B.P. Observations on the nature, biosynthesis, secretion and significance of endogenous ouabain. Clinical and Experimental Hypertension 20 (1998) 523-533
51. +-ATPase with high sodium intake in patients with essential hypertension. Journal of Clinical Hypertension 3 (1987) 419-424
52. Haupert G.T., and Sancho J. Sodium transport inhibitor from bovine hypothalamus. Proceedings of the National Academy of Sciences 76 (1979) 4658-4660
53. +)-ATPase. American Journal of Physiology 247 (1984) F919-F924
54. Hilton P.J., White R.W., Lord G.A., Garner G.V., Gordon D.B., Hilton M.J., Forni L.G., McKinnon W., Ismail F.M.D., Keeman M., Jones K., and Morden W.E. An inhibitor of the sodium pump obtained from human placenta. Lancet 348 (1996) 303-305
55. Holland S., Millett J., Olaghband J., deWardener H., Pamnani M., and Haddy F. Cytochemically detectable glucose 6-phosphate dehydrogenase stimulating Na-K-ATPase inhibiting activity in plasma and hypothalamus in reduced renal mass hypertension. American Journal of Hypertension 4 (1991) 315-320
56. Huang B.S., Kudloc M., Kumarathosan R., and Leenen F.H. Digoxin prevents ouabain and high salt intake-induced hypertension in rats with sinoaortic denervation. Hypertension 34 (1999) 733-738
57. + pump and a ouabain-like humoral agent in the genesis of reduced renal mass hypertension. American Journal of Physiology 3 (1983) 92-99
58. + pump activity in reduced renal mass hypertension. Hypertension 5 suppl 1 (1983) 94-100
59. Jones A.W. Altered ion transport in vascular smooth muscle from spontaneously hypertensive rat. Circulation Research 33 (1973) 563-572
60. Jones A.W. Altered ion transport in large and small arteries from spontaneously hypertensive rats and the influence of calcium. Circulation Research 24 & 25 suppl 1 (1974) 1-117-1-122
61. Jones A.W. Kinetics of active sodium transport in aorta from control and deoxycorticosterone hypertensive rats. Hypertension 3 (1981) 631-640
62. Jones R.B., Patrick J., and Hilton P.J. Increased sodium content and altered sodium transport of spontaneously hypertensive rat. Clinical Science 61 (1981) 313-316
63. Komiyamo Y., Nichimura N., Dong X.H., Hirose S., Kosaka C., Masake H., Masuda M., and Takahashi H. Liquid chromatography mass spectrometric analysis of ouabain-like factor in biological fluid. Hypertension Research 23 (2000) S21-S27 (Suppl)
64. Komiyamo Y., Dong X.H., Nishimura N., Masaki H., Yoshiko M., Masuda M., and Takahashi H. A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patient with terminal renal failure. Clinical Biochemistry 38 (2005) 36-45
65. Kowamura A., Guo J., Itagaki Y., Bell C., Wang Y., Haupert J., Garner T., Magil S., Gallagher R.T., Berova N., and Nakanishi K. On the structure of endogenous ouabain. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 6654-6659
66. Leenan F.J., Harmsen E., Yu H., and Yuan B. Dietary sodium stimulates ouabain like activity in adrenalectomized spontaneously hypertensive rats. American Journal of Physiology 265 (1993) H421-H424
67. +-ATPase: the link between sodium and vascular tone in experimental and inherited hypertension?. In: Villarreal H., and Sambi M.P. (Eds). Topics in Pathophysiology of Hypertension (1984), Martinus Nyhoff Publishers, Boston 239-260
68. MacGregor G.A., Fenton S., Olaghband-Zadeh J., Marbandu N., Roulston J.E., and deWardener H.E. Evidence for a raised concentration of a circulating sodium transport inhibitor in essential hypertension. British Medical Journal 283 (1981) 1355-1357
69. McKinnon W., Lord G.A., Forni L.G., and Hilton P.J. Circulating sodium pump inhibitors in five volume-expanded humans. Journal of Hypertension 21 (2003) 2315-2321
70. Manunta P., Rogowski A.C., Hamilton B.P., and Hamlyn J.M. Ouabain-induced hypertension in the rat: relationships among plasma and tissue ouabain and blood pressure. Journal of Hypertension 12 (1994) 549-560
71. Manunta P., Stella P., Rivera R., Ciurlino D., Gusi D., Ferrandi M., Hamlyn J.M., and Bianchi G. Left ventriclular mass, stroke volume, and ouabain-like factor in essential hypertension. Hypertension 34 (1999) 450-456
72. Manunta P., Hamilton J., Rogowski A.C., Hamilton B.P., and Hamlyn J.M. Chronic hypertension induced by ouabain but not digoxin in the rat: antihypertensive effect of digoxin and digitoxin. Hypertension Research, Clinical and Experimental 23 (2000) S77-S85
73. Manunta P., Messaggio E., Ballabeni C., Sciarrone M.T., Lanzani C., Ferrandi M., Hamlyn J.M., Cusi D., Galletti F., and Bianchi G. Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension 38 (2001) 198-203
74. In: Meyer P., and Garay R.P. (Eds). Genetic markers in essential hypertension. Clinical and Experimental Hypertension vol. 4 (3) (1981)
75. Oda M., Kurosawa M., Numazowa S., Tanaka S., Akizawa T., Ito K., Maeda M., and Yoshida T. Determination of bufalin-like immunoreactivity in serum of humans and rats by time-resolved fluoroimmunoassay for using a monoclonal antibody. Life Science 68 (2001) 1107-1117
76. Overbeck H.W., Pamnani M.B., Akera T., Brody T.M., and Haddy F.J. Depressed function of a ouabain-sensitive sodium-potassium pump in blood vessels from renal hypertensive dogs. Circulation Research 38 suppl 2 (1976) 48-52
77. Pamnani M.B., Clough D.L., Huot S.J., and Haddy F.J. Vascular sodium-pump activity in various models of experimental hypertension. Clinical Science 59 (1980) 179s-181s
78. + pump activity in Dahl S&R rats. Proceedings of the Society for Experimental Biology and Medicine 165 (1980) 440-444
79. + transport factor(s) in one kidney, one wrapped hypertension dogs. Physiologist 23 4 (1980) 91
80. Pamnani M.B., Buggy J., Huot S.J., and Haddy F.J. Studies on the role of a humoral sodium transport inhibitor and the anteroventral third ventricle (AV3V) in experimental low-renin hypertension. Clinical Science 61 (1981) 57s-60s
81. Pamnani M.B., Clough D.L., Huot S.J., and Haddy F.J. Sodium-potassium pump activity in experimental hypertension. In: Vanhoutte P.M., and Leusen I. (Eds). Vasodilatation (1981), Raven Press, New York 391-403
82. + pump in some models of experimental hypertension. Hypertension 3 suppl 2 (1981) 96-101
83. Pamnani M.B., Harder D.R., Huot S.H., Bryant H.J., Kutyna F.A., and Haddy F.J. Vascular smooth muscle membrane potential and a ouabain like humoral factor in one-kidney, one clip hypertension in rats. Clinical Science 63 (1982) 31s-33s
84. + pump inhibiting factor (HPIF) following acute volume expansion in humans. Federation Proceedings 43 (1984) 647
85. + pump inhibitor in essential hypertension and in normotensive subjects following acute volume expansion. American Journal of Hypertension 2 (1989) 524-531
86. Pamnani M.B., Whitehorn W., Clough D., and Haddy F.J. Effect of canrenone in rats with reduced renal mass saline hypertension. American Journal of Hypertension 3 (1990) 188-195
87. Pamnani M.B., Chen S., Bryant H.G., Schooley J.F., Eliades D.C., and Haddy F.J. Effects of three sodium potassium adenosine triphosphatase inhibitors. Hypertension 18 (1991) 316-324
88. Pamnani M.B., Chen S., Yuan C.M., and Haddy F.J. Chronic blood pressure effects of bufalin, a sodium-potassium ATPase inhibitor, in rats. Hypertension 23 (1994) I106-I109
89. Pamnani M.B., Chen X., Haddy F.J., Schooley J.F., and Mo Z. Mechanism of antihypertensive effect of dietary potassium in experimental volume expanded hypertension in rats. Clinical and Experimental Hypertension 22 (2000) 555-569
90. Postnov Y.V., Orlov S., Gulak P., and Shevchenko A. Altered permeability of erythrocyte membrane in spontaneously hypertensive rats. Pflugers Archiv 365 (1976) 257-263
91. Poston I., Sewell R.B., Wilkinson S.P., Richardson R.J., Williams R., Clarkson E.M., MacGregor G.A., and deWardener H.E. Evidence for a circulating sodium transport inhibitor in essential hypertension. British Medical Journal 282 (1981) 847-849
92. Quzzaz H.M.A.M., Goudy S.L., and Valdes R.J. Deglycosylated products of endogenous digoxin-like immunoreactive factor in mammalian tissue. Journal of Biological Chemistry 271 (1996) 8731-8737
93. Schneider R., Wray V., Nimtz M., Lehmann W.D., Kircht U., Antolovic R., and Schoner W. Bovine adrenals contain, in addition to ouabain, a second inhibitor of the sodium pump. Journal of Biological Chemistry 273 (1998) 784-792
94. Schoner W. Endogenous cardiac glycosides, a new class of steroid hormones. European Journal of Biochemistry 269 (2002) 2440-2448
95. Semplicini A., Buzzaccarini F., Ceolotto G., Marzola M., Mozzoto M.G., Giwsto M., Campagnolo M., Simonella C., and Pessina A.C. Effects of canrenoate on red cell sodium transport and calf blood flow in essential hypertension. American Journal of Hypertension 6 (1993) 295-301
96. Shaikh I.M., Low B.W.C., Siegfried B.A., and Valdes R. Isolation of digoxin-like immunoreactive factors in mammalian adrenal cortex. Journal of Biological Chemistry 266 (1991) 13672-13678
97. Sich B., Kirch U., Tepel M., Ziedek W., and Schoner W. Pulse pressure correlates with a proscillaridin immunoreactive compound. Hypertension 27 (1996) 1073-1078
98. + pump activity. Hypertension 4 (1982) 575-589
99. Soszynski T., Slovinska-Srednicka J., and Sgliznski S. Increased activity of digoxin-like substance in low-renin hypertension in acromegaly. Clinical and Experimental Hypertension 12 (1990) 533-549
100. Tymiak A.A., Norman J.A., Bolgar M., Didonato G., Lee H., Parker W.L., Lo L.-C., Berova N., Nakanishi K., Haber E., and Haupert Jr. G.T. Proceedings of the National Academy of Sciences of the United States of America 90 (1993) 8189-8193
101. Valdes Jr. R. Endogenous digoxin-immunoactive factor in human subjects. Federation Proceedings 44 (1985) 2800-2805
102. Veerasingham S.J., and Leenen F.H. Ouabain- and central sodium-induced hypertension depend on ventral anteroventral third ventricle region. American Journal of Physiology 276 (1999) H63-H70
103. Yamori Y., Nara Y.R., and Ohtaka M. Ion permeability of erythrocyte membrane in spontaneously hypertensive rat. Japanese Heart Journal 18 (1977) 604-605
104. Yuan C.M., Manunta P., Hamlyn J.M., Chen S., Bohen E., Yeun J., Haddy F.J., and Pamnani M.B. Long term ouabain produces hypertension in rats. Hypertension 22 (1993) 178-187
105. Zhao N., Lo L.-C., Berova N., Nakanishi K., Tymiak A.A., Ludens J.H., and Haupert Jr. G.T. Na,K-ATPase inhibitors from bovine hypothalamus and human plasma are different from ouabain: nanogram scale CD structural analysis. Biochemistry 34 (1995) 9893-9896